Astrazeneca (AZN) Acquisitions (2009 - 2026)

Astrazeneca (AZN) has reported Acquisitions for 17 consecutive years, with $7.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Acquisitions rose 44.55% year-over-year to $7.6 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 28.92% YoY), while the FY2025 annual figure was -$66.0 million, up 97.62% from the prior year.
• Acquisitions came in at $7.6 billion for Q1 2026 at Astrazeneca, up from -$6.0 million in the prior quarter.
• The five-year high for Acquisitions was $7.6 billion in Q1 2026, with the low at -$7.1 billion in Q3 2025.
• Average Acquisitions over 5 years is $935.1 million, with a median of -$97.5 million recorded in 2023.
• Across the five-year window, Acquisitions slumped 284.13% in 2024 and jumped 820.39% in 2025, its largest moves.
• Year by year, Acquisitions stood at -$945.0 million in 2022, then jumped by 80.0% to -$189.0 million in 2023, then sank by 982.01% to -$2.0 billion in 2024, then soared by 99.71% to -$6.0 million in 2025, then surged by 126100.0% to $7.6 billion in 2026.
• According to Business Quant data, Acquisitions over the past three periods registered $7.6 billion, -$6.0 million, and -$7.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.